DataSheet_1_Dynamic immune signatures of patients with advanced non–small-cell lung cancer for infection prediction after immunotherapy.docx

BackgroundPulmonary infections are a crucial health concern for patients with advanced non–small-cell lung cancer (NSCLC). Whether the clinical outcome of pulmonary infection is influenced by immunotherapy(IO) remains unclear. By evaluating immune signatures, this study investigated the post-immunotherapy risk of pulmonary infection in patients with lung cancer and identified circulating biomarkers that predict post-immunotherapy infection.MethodsBlood specimens were prospectively collected from patients with NSCLC before and after chemotherapy(C/T) and/or IO to explore dynamic changes in immune signatures. Real-world clinical data were extracted from medical records for outcome evaluation. Mass cytometry and ELISA were employed to analyze immune signatures and cytokine profiles to reveal potential correlations between immune profiles and the risk of infection.ResultsThe retrospective cohort included 283 patients with advanced NSCLC. IO was associated with a lower risk of pneumonia (odds ratio=0.46, p=0.012). Patients receiving IO and remained pneumonia-free exhibited the most favorable survival outcomes compared with those who received C/T or developed pneumonia (p+CD8+(cytotoxic) T cells (p+CD4+ T cells (p+ and PD-1+ cytotoxic T cells (p+CD4+ T cells (p+ cytotoxic T cells significantly increased in patients with pneumonia after treatment(p+ cytotoxic T cells significantly decreased in patients without pneumonia after treatment (pConclusionsOur results indicate that the incorporation of immunotherapy into treatment regimens may potentially offer protective effects against pulmonary infection. Protective effects are associated with reduction of exhausted T-cells and augmentation of TNF-α and NK cells. Exhausted T cells, NK cells, and TNF-α may play crucial roles in immune responses against infections. These observations highlight the potential utility of certain circulating biomarkers, particularly exhausted T cells, for predicting post-treatment infections.</p

sj-doc-6-tar-10.1177_17534666231209150 – Supplemental material for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia

Supplemental material, sj-doc-6-tar-10.1177_17534666231209150 for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia by Hsiao-Chin Shen, Jia-Yih Feng, Chuan-Yen Sun, Jhong-Ru Huang, Yuh-Min Chen, Wei-Chih Chen and Kuang-Yao Yang in Therapeutic Advances in Respiratory Disease</p

sj-docx-4-tar-10.1177_17534666231209150 – Supplemental material for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia

Supplemental material, sj-docx-4-tar-10.1177_17534666231209150 for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia by Hsiao-Chin Shen, Jia-Yih Feng, Chuan-Yen Sun, Jhong-Ru Huang, Yuh-Min Chen, Wei-Chih Chen and Kuang-Yao Yang in Therapeutic Advances in Respiratory Disease</p

sj-docx-1-tar-10.1177_17534666231209150 – Supplemental material for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia

Supplemental material, sj-docx-1-tar-10.1177_17534666231209150 for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia by Hsiao-Chin Shen, Jia-Yih Feng, Chuan-Yen Sun, Jhong-Ru Huang, Yuh-Min Chen, Wei-Chih Chen and Kuang-Yao Yang in Therapeutic Advances in Respiratory Disease</p

sj-png-5-tar-10.1177_17534666231209150 – Supplemental material for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia

Supplemental material, sj-png-5-tar-10.1177_17534666231209150 for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia by Hsiao-Chin Shen, Jia-Yih Feng, Chuan-Yen Sun, Jhong-Ru Huang, Yuh-Min Chen, Wei-Chih Chen and Kuang-Yao Yang in Therapeutic Advances in Respiratory Disease</p

sj-docx-2-tar-10.1177_17534666231209150 – Supplemental material for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia

Supplemental material, sj-docx-2-tar-10.1177_17534666231209150 for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia by Hsiao-Chin Shen, Jia-Yih Feng, Chuan-Yen Sun, Jhong-Ru Huang, Yuh-Min Chen, Wei-Chih Chen and Kuang-Yao Yang in Therapeutic Advances in Respiratory Disease</p

sj-docx-3-tar-10.1177_17534666231209150 – Supplemental material for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia

Supplemental material, sj-docx-3-tar-10.1177_17534666231209150 for Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia by Hsiao-Chin Shen, Jia-Yih Feng, Chuan-Yen Sun, Jhong-Ru Huang, Yuh-Min Chen, Wei-Chih Chen and Kuang-Yao Yang in Therapeutic Advances in Respiratory Disease</p

Additional file 1 of Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective cohort study

Additional file 1. Materials and methods

Comorbidities and risk of mortality in patients with sleep apnea

Background: A variety of disorders, most notably cardiovascular diseases, was linked to sleep apnea (SA), but their impact on mortality of SA patients had not been systematically investigated. We aimed to develop a composite index based on the comorbidity burden to predict mortality risk. Methods: Using Taiwan National Health Insurance Research Database, 9853 adult SA patients were enrolled and their comorbidity profile at baseline was recorded. The subjects were followed from 1995 till death or the end of 2011. A Cox regression model was used for multivariable adjustment to identify independent predictors for mortality. Results: During an average follow-up period of 5.3 ± 3.1 years, 311 (3.2%) subjects died. SA patients with any comorbidity had a higher risk for death compared to those without comorbidity (HR: 11.01, 95% CI 4.00–30.33, p 6 were 1 (reference), 3.29 (95% CI, 2.04–5.28, p  Conclusions: Based on the comorbidity burden, we developed an easy-to-use tool to evaluate mortality risk in SA.Key messages:Sleep apnea (SA) is linked to a variety of disorders, particularly cardiovascular diseases. SA patients with any comorbidity may experience a higher risk of death in comparison to those without comorbidity.Comorbidities related to increased mortality are identified and converted into a simple risk indicator, the CoSA (Comorbidities of Sleep Apnea) index scores, which may help to stratify risk of death in daily practice. Sleep apnea (SA) is linked to a variety of disorders, particularly cardiovascular diseases. SA patients with any comorbidity may experience a higher risk of death in comparison to those without comorbidity. Comorbidities related to increased mortality are identified and converted into a simple risk indicator, the CoSA (Comorbidities of Sleep Apnea) index scores, which may help to stratify risk of death in daily practice.</p

Data_Sheet_1_Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors.DOCX

BackgroundThe aim of study is to investigate the influence of pulmonary function on the prognosis in patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).Patients and MethodsData were collected retrospectively from 151 patients with stage IV NSCLC who received ICI and completed spirometry before ICI therapy in Taipei Veterans General Hospital between January 2016 and December 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS) between groups divided by 80% predicted FEV1 since ICI therapy started; the secondary outcomes were objective response rate.ResultsAmong 151 patients enrolled to this study, 67.5% of patients were men, 75.5% were adenocarcinoma, 24.5% had known targetable driver mutation, 33.8% received first-line ICI, and 62.8% received ICI monotherapy. The objective response rate was 24.5% and disease control rate was 54.3%. In multivariable analysis, patient with reduced FEV1 had inferior PFS (FEV1 1 ≥ 80%, adjusted HR = 1.80, P = 0.006) and OS (FEV1 1 ≥ 80%, adjusted HR = 2.50, P 1 group (≥80% predicted FEV1) compared to the reduced FEV1 group (1) were 5.4 vs. 2.9 months (HR = 1.76, P = 0.003) and 34.9 vs. 11.1 months (HR = 2.44, P ConclusionsReduced FEV1 is strongly associated with inferior clinical outcomes in patients with advanced NSCLC treated with ICI.</p